| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
{Boc}-Phe-Leu-Phe-Leu-Phe targets the formyl peptide receptor (FPR) family, which are G protein-coupled receptors that play a key role in the innate immune response. These receptors are activated by bacterial and mitochondrial formylated peptides, leading to the chemotaxis and activation of neutrophils and other immune cells. This peptide acts as a family antagonist, preferentially inhibiting the activity triggered through these receptors.
|
|---|---|
| ln Vitro |
In vitro, {Boc}-Phe-Leu-Phe-Leu-Phe functions as a selective antagonist of the FPR family, effectively inhibiting receptor activity in response to formyl peptides. It is used to block FPR-mediated signaling pathways, such as calcium mobilization and chemotaxis, in various cell types, including neutrophils. Its antagonistic activity confirms the role of FPRs in mediating the effects of formylated peptides.
|
| ln Vivo |
In vivo activity data for {Boc}-Phe-Leu-Phe-Leu-Phe are not extensively detailed in the search results. As a specific antagonist of the FPR family, it is a critical research tool for investigating the role of these receptors in various inflammatory and infectious disease models. It is used to block FPR signaling in vivo to study its function in conditions such as sepsis, arthritis, and other inflammatory diseases.
|
| Enzyme Assay |
For non-cellular in vitro receptor binding assays, {Boc}-Phe-Leu-Phe-Leu-Phe is used to characterize its binding affinity and antagonistic properties at FPRs. Typically, this involves radioligand binding displacement assays, where the ability of the peptide to compete with a labeled agonist, such as [3H]-fMLF, for binding to the receptor is measured. This helps to confirm its specificity and affinity for the FPR family.
|
| Cell Assay |
For in vitro cellular assays, the activity of {Boc}-Phe-Leu-Phe-Leu-Phe is evaluated in cells expressing FPRs, such as human neutrophils or differentiated HL-60 cells. A typical assay involves measuring the inhibition of agonist-induced intracellular calcium mobilization. Cells are loaded with a calcium-sensitive fluorescent dye, and the increase in fluorescence upon addition of an agonist like fMLF is measured. The peptide is added prior to the agonist to assess its ability to block this response.
|
| Animal Protocol |
In vivo animal studies with {Boc}-Phe-Leu-Phe-Leu-Phe are typically conducted in mouse models of inflammatory diseases. For example, it may be administered to mice to block FPR signaling in models of acute lung injury, peritonitis, or ischemia-reperfusion injury. The compound is commonly administered via routes such as intraperitoneal injection, and its efficacy is assessed by measuring inflammatory markers and tissue damage.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for {Boc}-Phe-Leu-Phe-Leu-Phe are not extensively documented. As a peptide, its oral bioavailability is likely low, and it would require parenteral administration for in vivo studies. Its stability and half-life are factors that would need to be considered in experimental design. The compound should be stored as a powder at -20°C for up to 3 years or at 4°C for 2 years.
|
| Toxicity/Toxicokinetics |
Toxicological data for {Boc}-Phe-Leu-Phe-Leu-Phe are limited. As a research compound, it is intended for laboratory use only and not for human therapeutic applications. Its safety profile has not been established for clinical use. At the concentrations used in research, it is generally considered to have low toxicity, but standard laboratory safety practices should always be followed.
|
| References | |
| Additional Infomation |
Formicoyl peptide antagonists and lipoxygen A4 receptor antagonists
{Boc}-Phe-Leu-Phe-Leu-Phe ({Boc}-FLFLF) is a selective formyl peptide receptor (FPR) family antagonist. With a molecular weight of 785.97, it is a key pharmacological tool for studying FPR-mediated signaling in inflammation and neutrophil biology. It preferentially inhibits activity triggered through FPRs and is widely used to block FPR function in vitro and in vivo. |
| Molecular Formula |
C44H59N5O8
|
|---|---|
| Molecular Weight |
785.97
|
| Exact Mass |
785.436
|
| CAS # |
66556-73-8
|
| Related CAS # |
{Boc}-Phe-Leu-Phe-Leu-Phe TFA
|
| PubChem CID |
125628
|
| Appearance |
White to off-white solid powder
|
| Density |
1.167 g/cm3
|
| Boiling Point |
1043.2ºC at 760 mmHg
|
| Flash Point |
584.7ºC
|
| Index of Refraction |
1.558
|
| LogP |
6.678
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
22
|
| Heavy Atom Count |
57
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CC(C)C[C@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)OC(C)(C)C
|
| InChi Key |
NGNZQSPFQJCBJQ-DWCHZDDLSA-N
|
| InChi Code |
InChI=1S/C44H59N5O8/c1-28(2)23-33(46-41(53)36(26-31-19-13-9-14-20-31)49-43(56)57-44(5,6)7)38(50)47-35(25-30-17-11-8-12-18-30)40(52)45-34(24-29(3)4)39(51)48-37(42(54)55)27-32-21-15-10-16-22-32/h8-22,28-29,33-37H,23-27H2,1-7H3,(H,45,52)(H,46,53)(H,47,50)(H,48,51)(H,49,56)(H,54,55)/t33-,34-,35+,36+,37+/m1/s1
|
| Chemical Name |
(2S)-2-[[(2R)-4-methyl-2-[[(2S)-2-[[(2R)-4-methyl-2-[[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]amino]-3-phenylpropanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (127.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (3.18 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2723 mL | 6.3616 mL | 12.7231 mL | |
| 5 mM | 0.2545 mL | 1.2723 mL | 2.5446 mL | |
| 10 mM | 0.1272 mL | 0.6362 mL | 1.2723 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
